Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05294991 · ClinicalTrials.gov registry record · NA
Wellness App for Sleep Disturbance in Hematological Cancer Patients
A NA study of Depression and Cancer, sponsored by The University of Texas Health Science Center at San Antonio.
- Recruiting
- Registry status
- NA
- Development phase
- 276
- Enrollment target
- 3
- Study locations
NCT05294991: Recruiting NA study of Depression and Cancer, sponsored by The University of Texas Health Science Center at San Antonio.
NCT05294991 is a NA study of Depression and Cancer that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 276 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (65% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05294991, a NA study of Depression and Cancer, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.
- RECRUITING
- Registry status
- NA
- Development phase
- 276 participants
- Enrollment target
- 3
- Study locations
Study Summary
In a randomized controlled trial (RCT), the investigators will recruit participants to an 8-week "app-based wellness" intervention, followed by a 12-week follow-up period. The investigators will recruit a total of 276 self-declared Chronic Hematological Cancer (CHC) patients who (representative of age, race/ethnicity, and gender) will be on stable CHC pharmacologic therapy (if any), self-identify as sleep disturbed (\>5 on Pittsburgh Sleep Quality Index), do not have a sleep disorder diagnosis, do not take sleep medication/supplements \>3 times per week, and are not currently practicing regular meditation. Aim 1: Test the efficacy of two app-based wellness programs (10 minutes per day) on the primary outcome of self reported sleep disturbance (Insomnia Severity Index (primary) and PROMIS Sleep Disturbance (secondary)) and secondary sleep outcomes including sleep impairment (PROMIS Sleep Impairment Scale) and sleep efficiency measured via sleep diaries and actigraphy. Aim 2: Test the efficacy of two app-based wellness programs (10 minutes per day) on inflammatory markers (i.e., TNF-a, IL-6, IL-8, CRP), fatigue, and emotional distress (i.e., anxiety, depressive symptoms measured with PROMIS®). Aim 3: Explore the sustained effects (i.e., 20 weeks from baseline) of two app-based wellness programs (10 minutes per day) in CHC patients.
Primary Outcome
Sleep disturbance will be measured with the Insomnia Severity Index (ISI). Total scores range from 0 to 28 with scores 8 to 14, and ≥15 indicating subclinical and moderate-to-severe insomnia symptom severity, respectively.
Conditions Studied
Interventions
- BEHAVIORAL Wellness app intervention #1
- BEHAVIORAL Wellness app intervention #2
Study Locations (3)
Arizona
- Arizona State University - Phoenix
North Carolina
- Wake Forest University School of Medicine - Winston-Salem
Texas
- Mays Cancer Center at The University of Texas Health Science Center at San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2023-02-20 |
| Est. Completion | 2026-10-31 |
| Phase | NA |
What NCT05294991 shows while recruiting
NCT05294991 is an interventional study that assigns participants to a tested intervention. The registered 276 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (65% lower).
The record links to 6 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Wellness app intervention #1 is the first listed.
NCT05294991 reports a single indexed study location in Arizona, North Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT05294991 about?
NCT05294991 is a clinical study titled "Wellness App for Sleep Disturbance in Hematological Cancer Patients". In a randomized controlled trial (RCT), the investigators will recruit participants to an 8-week "app-based wellness" intervention, followed by a 12-week follow-up period. The investigators will recruit a total of 276 self-declared Chronic Hematological Cancer (CHC) patients who (representative of a...
What is the current status of trial NCT05294991?
This trial is currently recruiting. It is a NA study. The enrollment target is 276 participants. The study started on 2023-02-20. Estimated completion is 2026-10-31.
What conditions does trial NCT05294991 study?
This clinical trial studies the following conditions: Depression, Cancer, Anxiety, Inflammation, Fatigue.
What interventions are being tested in trial NCT05294991?
The interventions under investigation include: Wellness app intervention #1 (BEHAVIORAL), Wellness app intervention #2 (BEHAVIORAL).
Who is sponsoring clinical trial NCT05294991?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05294991 being conducted?
This trial has 3 study locations across Arizona, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05294991's enrollment target sits among peer trials
276 163rd of 679 higher than 517 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
Cold and Heat Investigation to Lower Levels of Depression
RECRUITING · NA
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01371630 · 276 participants · Phase 1
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
- NCT04192344 · 276 participants · Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
- NCT05610852 · 276 participants · NA
Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
- NCT05611931 · 276 participants · Phase 3
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy